Literature DB >> 15151528

Bisphosphonate use and subsequent prescription of acid suppressants.

E E Roughead1, K McGeechan, G P Sayer.   

Abstract

AIM: To determine the extent of prescribing of acid suppression agents associated with initiation of bisphosphonate therapy.
METHODS: This was a case control study, performed within the General Practice Network, Australia. The main outcome measure was re-attendance within six weeks from index bisphosphonate prescription for acid supression agents.
RESULTS: Of the bisphosphonate cases, 2.9%[95% confidence interval (CI) 1.8, 3.9] returned within 6 weeks for a prescription for proton pump inhibitor, histamine 2 receptor antagonist or antacid, compared with 0.9% of control patients (95% CI 0.5, 1.2). However, the bisphosphonate cases had significantly higher rates of previous use of nonsteroidal anti-inflammatory agents. After controlling for previous nonsteroidal anti-inflammatory drug use, the increased use of acid suppression agents was statistically significant, the odds ratio = 3.21 (95% CI 2.02, 5.11).
CONCLUSION: Bisphosphonate use appears to be associated with increased use of acid suppressant agents within 6 weeks of first supply.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15151528      PMCID: PMC1884527          DOI: 10.1111/j.1365-2125.2004.02078.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.

Authors:  Hugh Taggart; Michael A Bolognese; Robert Lindsay; Mark P Ettinger; Henk Mulder; Robert G Josse; Anthony Roberts; Hartmut Zippel; Silvano Adami; Teresa F Ernst; Karen P Stevens
Journal:  Mayo Clin Proc       Date:  2002-03       Impact factor: 7.616

2.  Alendronate and naproxen are synergistic for development of gastric ulcers.

Authors:  D Y Graham; H M Malaty
Journal:  Arch Intern Med       Date:  2001-01-08

3.  Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.

Authors:  D C Bauer; D Black; K Ensrud; D Thompson; M Hochberg; M Nevitt; T Musliner; D Freedholm
Journal:  Arch Intern Med       Date:  2000-02-28

4.  The General Practice Research Network: the capabilities of an electronic patient management system for longitudinal patient data.

Authors:  Geoffrey P Sayer; Kevin McGeechan; Andrew Kemp; Alice Bhasale; Fiona Horn; Leigh Hendrie; Lisa Swan; Sharon Scahill
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003-09       Impact factor: 2.890

Review 5.  Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.

Authors:  Raheem B Kherani; Alexandra Papaioannou; Jonathan D Adachi
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 6.  Esophagitis associated with the use of alendronate.

Authors:  P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

7.  Evaluation of a patient event report monitoring system.

Authors:  K A Colebatch Bpharm McLin Pharm; J Marley Md Mbchb; C Doecke; H Miles Bsc; A Gilbert Bpharm Phd
Journal:  Pharmacoepidemiol Drug Saf       Date:  2000-11       Impact factor: 2.890

8.  United Kingdom experience with alendronate and oesophageal reactions.

Authors:  F J Mackay; L V Wilton; G L Pearce; S N Freemantle; R D Mann
Journal:  Br J Gen Pract       Date:  1998-04       Impact factor: 5.386

  8 in total
  8 in total

1.  Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.

Authors:  C Roux; J L Goldstein; X Zhou; A Klemes; R Lindsay
Journal:  Osteoporos Int       Date:  2011-03-02       Impact factor: 4.507

2.  Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis.

Authors:  Si-Dong Yang; Qian Chen; Hai-Kun Wei; Feng Zhang; Da-Long Yang; Yong Shen; Wen-Yuan Ding
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.

Authors:  L-A Fraser; W D Leslie; L E Targownik; A Papaioannou; J D Adachi
Journal:  Osteoporos Int       Date:  2012-08-14       Impact factor: 4.507

4.  Serum level of pepsinogen significantly associated with gastric distress induced by amino-bisphosphonates.

Authors:  M Shiraki; Y Yamazaki; T Kuroda; S Tanaka; K Miyata
Journal:  Osteoporos Int       Date:  2010-09-03       Impact factor: 4.507

5.  A study of codispensing with sodium alendronate in Australia.

Authors:  Ian W Boyd; John McEwen; Lisa J Calcino
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

6.  Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates.

Authors:  F de Vries; A L Cooper; S M Cockle; T-P van Staa; C Cooper
Journal:  Osteoporos Int       Date:  2009-03-31       Impact factor: 4.507

Review 7.  Proton Pump Inhibitors and Bone Health: An Update Narrative Review.

Authors:  Eric Lespessailles; Hechmi Toumi
Journal:  Int J Mol Sci       Date:  2022-09-14       Impact factor: 6.208

8.  Association between proton pump inhibitor use and risk of fracture: A population-based case-control study.

Authors:  Jong Joo Kim; Eun Jin Jang; Jiwon Park; Hyun Soon Sohn
Journal:  PLoS One       Date:  2020-07-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.